Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout

Background: With the prevalence of and hospitalizations for gout increasing, optimizing care for patients with gout is imperative. The 2012 American College of Rheumatology gout guidelines emphasize that timely monitoring is key to achieving serum urate (SUA) goals. Few studies have examined this me...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy 2017-04, Vol.51 (4), p.301-306
Main Authors: Hughes, Jonathan C., Wallace, Jessica L., Bryant, Candace L., Salvig, Brent E., Fourakre, T. Neal, Stone, William J.
Format: Article
Language:English
Subjects:
Adult
Aged
Allopurinol - administration & dosage
Allopurinol - adverse effects
Allopurinol - therapeutic use
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Drug Monitoring
Febuxostat - administration & dosage
Febuxostat - adverse effects
Febuxostat - therapeutic use
Female
Gout - blood
Gout - drug therapy
Gout Suppressants - administration & dosage
Gout Suppressants - adverse effects
Gout Suppressants - therapeutic use
Humans
Male
Retrospective Studies
Rheumatology
Tennessee
Uric Acid - blood
Veterans
Xanthine Oxidase - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: With the prevalence of and hospitalizations for gout increasing, optimizing care for patients with gout is imperative. The 2012 American College of Rheumatology gout guidelines emphasize that timely monitoring is key to achieving serum urate (SUA) goals. Few studies have examined this metric following the 2012 update, and to our knowledge, none have examined a veteran population. Objective: To evaluate adherence to urate-lowering therapy (ULT) monitoring guidelines in a veteran population. Methods: This is a single-center, multisite, retrospective chart review of US veterans receiving ULT for gout within the VA (Veterans Affairs) Tennessee Valley Healthcare System from January 1, 2013, to June 30, 2015. The primary end point was percentage of patients with a SUA within 6 months of initial xanthine oxidase inhibitor prescription. Secondary end points included percentage of patients with SUA
ISSN:1060-0280
1542-6270
DOI:10.1177/1060028016679848